[A24-118] Dupilumab (COPD) - Addendum to Project A24-79
Last updated 06.02.2025
Project no.:
A24-118
Commission:
Commission awarded on 10.12.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Add-on maintenance treatment of adult patients with uncontrolled COPD characterized by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta-2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if an inhaled corticosteroid is not appropriate
After addendum now:
- Patients who are not eligible for treatment with roflumilast: hint of minor added benefit
- Patients who are eligible for treatment with roflumilast: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-118_en
| Project no. | Title | Status |
|---|---|---|
| A24-79 | Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-02-06 A G-BA decision was published.